HDAC9 and acute myeloid leukemia: In younger AML patients, multidrug regimens combining anthracyclines and IDAC or HDAC have shown similar or even greater efficacy than IDAC/HDAC, notably in high‐risk patients, but with increased toxicity.13, 14, 15